Ads
related to: thalassemia
Search results
Vertex Is Writing A New Playbook For Pharma R&D. And It’s Working.
Forbes· 5 days agoFounded in 1989, Vertex’s rollercoaster story is most iconically characterized by the rise and fall...
2 Unbelievable Growth Stocks You Can Buy and Hold for the Next Decade
Motley Fool via Yahoo Finance· 6 days agoIt's in the process of launching its new gene editing therapy Casgevy, which it developed with...
Health Benefits of Gelatin
Health via Yahoo News· 4 days agoGelatin may help improve bone and muscle conditions, boost your skin health, and support your gut. However, research on this ingredient is still limited.
How Gene Editing Therapies Could Go Beyond Rare Diseases
Forbes· 3 days agoEarlier this year, a group of scientists in the Netherlands used the gene editing tool CRISPR to...
How Toxins Can Cause Heart Failure and Cardiomyopathy
Mercola· 4 days agoAccording to research1 published in 1999, people with severe heart failure have 12,000-fold more antimony in their myocytes (the heart muscle cells responsible for contraction) than healthy ...
Vertex Stock Hit All-Time High, Paused, Rising Again
Investor's Business Daily· 4 days agos quickly rising toward that major milestone. Vertex makes drugs to treat cystic fibrosis, a disease that affects a person's glands including ones that...
New York State Common Retirement Fund Has $263,000 Holdings in bluebird bio, Inc. (NASDAQ:BLUE)
ETF DAILY NEWS· 2 days agoNew York State Common Retirement Fund boosted its holdings in shares of bluebird bio, Inc. (NASDAQ:BLUE – Free Report) by 67.0% during the 4th quarter, according to its most recent disclosure ...
Beam Therapeutics Inc. (NASDAQ:BEAM) Receives Average Recommendation of “Hold” from Brokerages
ETF DAILY NEWS· 5 days agoShares of Beam Therapeutics Inc. (NASDAQ:BEAM – Get Free Report) have been given a consensus rating of “Hold” by the thirteen ratings firms that are covering the stock, MarketBeat Ratings reports ...
Q2 2024 EPS Estimates for Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Boosted by Leerink Partnrs
ETF DAILY NEWS· 2 days agoFulcrum Therapeutics, Inc. (NASDAQ:FULC – Free Report) – Analysts at Leerink Partnrs raised their Q2 2024 earnings per share estimates for shares of Fulcrum Therapeutics in a research note issued ...
FY2024 EPS Estimates for Beam Therapeutics Inc. (NASDAQ:BEAM) Cut by Cantor Fitzgerald
ETF DAILY NEWS· 4 days agoBeam Therapeutics Inc. (NASDAQ:BEAM – Free Report) – Equities researchers at Cantor Fitzgerald cut their FY2024 EPS estimates for shares of Beam Therapeutics in a research note issued to investors ...
